"These estimates suggest that current levels of insulin access are highly inadequate compared to projected need, particularly in Africa and Asia", Basu said.
The study said 79 million people with type- 2 diabetes will need insulin by 2030, while insulin required to treat the patients is expected to increase by around 20%. According to the calculation of Sanjay Basu from Stanford University in California, the number of people who will need insulin to treat type 2 diabetes will climb by 20 percent in the next decade. Their study was published Tuesday in The Lancet Diabetes & Endocrinology journal.
The researchers have warned that new strategies must be adopted to make insulin more widely available and affordable.
"These assessments propose that current dimensions of insulin access are exceptionally insufficient contrasted with anticipated need, especially in Asia and Africa, and more endeavors ought to be dedicated to defeating this approaching health challenge", states Dr. Sanjay Basu from Stanford University, USA main lead of the study.
Dr. Sanjay Basu from Stanford University in the U.S. said that these approximates proposes that present level of insulin retrieval are extremely scanty contrasted to estimated requirement especially in Africa and Asia, and more attempts should be committed to vanquishing this emerging health provocation.
India had 69.2 million people living with diabetes in 2015 says a report of the World Health Organization
Insulin is very much essential for patients to combat type 2 diabetes and it will help the diabetic victims to reduce complications associated with this disease like kidney failure, blindness and stroke.
In the next 12 years, half of those with type 2 diabetes won't be able to receive potentially life-saving insulin unless access to the drug improves, new research shows.
Insulin is used to treat those with Type 1 diabetes and some people with Type 2 diabetes, which is linked to obesity and little physical activity. The study found that the rise in the number of people affected by the disease is likely to rise by around 20 per cent over the people affected now.
Right now, three major manufacturers dominate the insulin market, and the treatment is expensive.
Diabetes is a progressive disease and the body may require insulin injections to compensate for declining insulin production by the pancreas.